<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03193099</url>
  </required_header>
  <id_info>
    <org_study_id>C16-115</org_study_id>
    <secondary_id>2017-A00589-44</secondary_id>
    <nct_id>NCT03193099</nct_id>
  </id_info>
  <brief_title>Decoding Presymptomatic White Matter Changes in Huntington Disease</brief_title>
  <acronym>Win-HD</acronym>
  <official_title>Decoding Presymptomatic White Matter Changes in Huntington Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University College, London</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      WIN-HD is a monocentric longitudinal study comparing premanifest Huntingtin (HTT) mutation
      carriers and non HTT mutation carriers to determine that white-matter atrophy occurs far
      earlier than clinical onset in HD using Diffusion-weighted Nuclear Magnetic Resonance (N
      spectroscopy (DWS) and Diffusion Tensor Imaging (DTI).

      The investigators will recruit up to 20 premanifest HTT mutation carriers (15 completed) and
      up to 20 non HTT mutation carriers (15 completed). It is important to have those 2
      populations in order to compare our results and determine if there are significant
      white-matter changes far from the onset of HD. Therefore, non HTT mutation carriers will be
      age and gender matched to premanifest HTT mutation carriers.

      In order to test the hypothesis, the study has 2 visits with a year interval.

      This study is based on 4 principal criteria:

        1. Imaging criteria

        2. Clinical and neurological criteria

        3. Psychological criteria

        4. Behavioral criteria
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 11, 2017</start_date>
  <completion_date type="Actual">December 30, 2019</completion_date>
  <primary_completion_date type="Actual">December 30, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Detection by Diffusion-weighted spectroscopy of abnormal white matter changes prior to the onset of Huntington disease comparing HTT mutation carriers and non HTT mutation carriers over one year</measure>
    <time_frame>one year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Detection by Diffusion-weighted spectroscopy of abnormal white matter changes over one year as an intersubject evolution</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection by Diffusion Tensor Imaging of abnormal white matter changes prior to the onset of Huntington disease comparing HTT mutation carriers and non HTT mutation carriers over one year.</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection by Diffusion Tensor Imaging white matter changes over one year as an intersubject evolution.</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of abnormal scores from psychological tests to assess possible early non motor changes and their intersubject evolution over one year.</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of choice rates and time differences in the behavioral task comparing HTT mutation carriers and non HTT mutation carriers over one year.</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Detection of time differences in the behavioral task comparing HTT mutation carriers and non HTT mutation carriers over one year.</measure>
    <time_frame>one year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Huntington Disease</condition>
  <condition>White Matter Alterations</condition>
  <arm_group>
    <arm_group_label>Premanifest HTT mutation carriers</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>non HTT mutation carriers</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Brain imaging</intervention_name>
    <description>Volume, DWS and DTI</description>
    <arm_group_label>Premanifest HTT mutation carriers</arm_group_label>
    <arm_group_label>non HTT mutation carriers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Neurological assessments</intervention_name>
    <description>UHDRS</description>
    <arm_group_label>Premanifest HTT mutation carriers</arm_group_label>
    <arm_group_label>non HTT mutation carriers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Psychological assessments</intervention_name>
    <description>STAI (Spielberger state and Trait Anxiety Inventory) A and B, BDI-II (Beck Depression Inventory), MINI (Mini-International Neuropsychiatric Interview) and MINI-SEA (mini Social cognitive and Emotional Assessment)</description>
    <arm_group_label>Premanifest HTT mutation carriers</arm_group_label>
    <arm_group_label>non HTT mutation carriers</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Behavioural assessments</intervention_name>
    <description>Computerized game</description>
    <arm_group_label>Premanifest HTT mutation carriers</arm_group_label>
    <arm_group_label>non HTT mutation carriers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  For presymptomatic individuals:

               -  Genetic test available with CAG (Cytosine-Adenine-Guanine) repeat length &gt; 36 in
                  HTT gene

               -  UHDRS score &lt;5

               -  Burden score &lt;250

          -  For controls:

             - Genetic test available with CAG repeat length ≤ 36 in HTT gene

          -  Common inclusion criteria for presymptomatic individuals and controls (age-matched and
             gender-matched with presymptomatic individuals and but without any familial
             relationship):

               -  At least 18 years of age

               -  Capacity to consent

               -  Signature of the informed consent

               -  Covered by social security

               -  Ability to undergo MRI scanning

        Non-Inclusion Criteria:

          -  Under the age of 18 years of age

          -  Contra-indications to MRI examination (metallic implant, pacemaker, artificial heart
             valve, brain vascular malformation, aneurysm clips, exposed by metallic fragments,
             artificial implants, peripheral or neuronal stimulator, insulin pump, intravenous
             catheter, epilepsy, person with an history of seizure, metallic contraceptive device,
             permanent eyelid make up, claustrophobia,…)

          -  Unwillingness to be informed in case of abnormal MRI (with a significant medical
             anomaly)

          -  History of severe head injury

          -  History of neurological disorder or presence of neurological disorder

          -  Participation in a drug trial or exclusion period of another study

          -  Pregnancy or breastfeeding

          -  Inability to understand information about the protocol

          -  Person deprived of their liberty by judicial or administrative decision

          -  Person under legal protection (legal guardianship, tutelage or maintenance of justice)

          -  Person without any protection and unable to consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandra DURR, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut National de la Santé Et de la Recherche Médicale, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brain and Spine Institute</name>
      <address>
        <city>Paris</city>
        <zip>750013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 13, 2017</study_first_submitted>
  <study_first_submitted_qc>June 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 20, 2017</study_first_posted>
  <last_update_submitted>February 17, 2020</last_update_submitted>
  <last_update_submitted_qc>February 17, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Huntington Disease</mesh_term>
    <mesh_term>Leukoaraiosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

